Published in TB and Outbreaks Week, October 25th, 1999
Moxifloxacin has been shown to have activity against a wide range of bacteria.
Researcher S.H. Gillespie and colleagues from London's Royal Free and University Medical School tested its activity in comparison with four other quinolones and isoniazid against clinical isolates of mycobacteria.
"It proved to be the most active of the quinolones tested against Mycobacterium tuberculosis (MIC90 0.25 mg/L), M. avium-intracellulare (MIC90 1.0 mg/L), M. kansasii (MIC90 0.06 mg/L), and M. fortuitum (MIC90 1 mg/L)," Gillespie et...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.